Contact
searchSearch
HMP Global

Health Care Economics

Conference Coverage
Inflation Reduction Act Readiness: Key Lessons From Early Medicare Drug Price Negotiations
04/30/2026
Hannah Musick
As manufacturers gain real-world experience with Inflation Reduction Act price negotiations, early lessons from the first 3 cycles highlight the need for earlier planning, stronger cross-functional coordination, and new approaches to data,...
As manufacturers gain real-world experience with Inflation Reduction Act price negotiations, early lessons from the first 3 cycles highlight the need for earlier planning, stronger cross-functional coordination, and new approaches to data,...
As manufacturers gain real-world...
04/30/2026
First Report Managed Care
Conference Coverage
MFN Pricing, IRA Negotiation, PBM Scrutiny, and 340B Remain Top Market Access Concerns
04/29/2026
Danielle Sposato
At Asembia 2026, market access leaders warned that sweeping policy shifts—from most favored nation (MFN) pricing and Inflation Reduction Act (IRA) negotiations to pharmacy benefit manager (PBM) and 340B reform—are reshaping global pricing...
At Asembia 2026, market access leaders warned that sweeping policy shifts—from most favored nation (MFN) pricing and Inflation Reduction Act (IRA) negotiations to pharmacy benefit manager (PBM) and 340B reform—are reshaping global pricing...
At Asembia 2026, market access...
04/29/2026
First Report Managed Care
Conference Coverage
Drug Pipeline Trends in Generics and Biosimilars Impacting Managed Care Strategies
04/15/2026
Grace Taylor, MS, MA
Delays in generic launches, evolving biosimilar adoption, and high-cost pipeline therapies are reshaping payer strategies and cost management across key therapeutic areas.
Delays in generic launches, evolving biosimilar adoption, and high-cost pipeline therapies are reshaping payer strategies and cost management across key therapeutic areas.
Delays in generic launches,...
04/15/2026
First Report Managed Care
Conference Coverage
Evaluating Copay Accumulators, Maximizers, and AFPs in Specialty Drug Cost Management
04/14/2026
Grace Taylor, MS, MA
Rising specialty drug costs are driving employers and payers toward cost-shifting strategies, but emerging evidence highlights potential trade-offs in patient access, adherence, and overall health care spending.
Rising specialty drug costs are driving employers and payers toward cost-shifting strategies, but emerging evidence highlights potential trade-offs in patient access, adherence, and overall health care spending.
Rising specialty drug costs are...
04/14/2026
First Report Managed Care
News
Study Projects Billions in Savings From Site-Neutral Payments for Routine Services
01/23/2026
Grace Taylor, MS, MA
A national analysis of 2022 commercial claims data suggests that capping payments for routine services at site-neutral Medicare-based rates could save purchasers and patients $10.8 billion annually with only modest effects on hospital margins.
A national analysis of 2022 commercial claims data suggests that capping payments for routine services at site-neutral Medicare-based rates could save purchasers and patients $10.8 billion annually with only modest effects on hospital margins.
A national analysis of 2022...
01/23/2026
First Report Managed Care
Long-Term Care, Post-Acute Care, Lobbying, Politics
Commentary
All Politics Is Local—Why Long-Term and Post-Acute Care Leaders Should Participate in Grassroots Advocacy
01/20/2026
Bill Charnetski
Local long-term and post-acute care leaders can’t afford to sit out politics—by embracing grassroots advocacy, sharing their expertise, and building relationships with lawmakers, they can directly shape the policies that affect their...
Local long-term and post-acute care leaders can’t afford to sit out politics—by embracing grassroots advocacy, sharing their expertise, and building relationships with lawmakers, they can directly shape the policies that affect their...
Local long-term and post-acute...
01/20/2026
Annals of Long-Term Care
News
DEA Extends Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026
01/13/2026
Danielle Sposato
The Drug Enforcement Administration (DEA), jointly with the Department of Health and Human Services (HHS), has issued a Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications. The...
The Drug Enforcement Administration (DEA), jointly with the Department of Health and Human Services (HHS), has issued a Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications. The...
The Drug Enforcement...
01/13/2026
First Report Managed Care
News
Rising Denials and Payer Audits Intensify Financial Strain on Hospitals in 2025
12/16/2025
Lisa Kuhns, PhD, MD
Hospitals are facing rising financial pressure as denial amounts and payer audits continue to climb in 2025, signaling an unsustainable trend for many health systems, according to a new report from billing compliance and revenue integrity...
Hospitals are facing rising financial pressure as denial amounts and payer audits continue to climb in 2025, signaling an unsustainable trend for many health systems, according to a new report from billing compliance and revenue integrity...
Hospitals are facing rising...
12/16/2025
First Report Managed Care
News
Survey Signals Turning Point in Public Opinion on Health Insurance and Debt Reform
11/20/2025
Lisa Kuhns, PhD, MD
Americans across political party lines overwhelmingly support stronger protections against medical debt, signaling rare consensus in a politically polarized era, according to a survey conducted by Undue Medical Debt. That is the clear...
Americans across political party lines overwhelmingly support stronger protections against medical debt, signaling rare consensus in a politically polarized era, according to a survey conducted by Undue Medical Debt. That is the clear...
Americans across political party...
11/20/2025
First Report Managed Care
News
HRSA Approves 340B Rebate Models, Reshaping Drug Discounts and Hospital Financing
11/03/2025
Juliet Gallagher
The Health Resources and Services Administration (HRSA) has approved 8 pharmaceutical manufacturer proposals to issue rebates under the 340B Drug Pricing Program, marking a significant departure from the long-standing model of upfront...
The Health Resources and Services Administration (HRSA) has approved 8 pharmaceutical manufacturer proposals to issue rebates under the 340B Drug Pricing Program, marking a significant departure from the long-standing model of upfront...
The Health Resources and...
11/03/2025
First Report Managed Care
Expert Perspectives
Commentary Videos

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use